ASU researchers develop DNA nanodevice for targeted cancer, disease treatment


Digital image of a nanorobot penetrating tissue cells.

Artist's conception of a DNA nanorobot designed for targeted, deep penetration into tumor tissue. Graphic by Lu Yu

|

Sixty years ago, the famous physicist Richard Feynman outlined his vision for the field of nanotechnology in his landmark lecture "There is plenty of room at the bottom." Feynman foresaw new exciting applications for nanoscale devices, even conjecturing, "Although it is a very wild idea, it would be interesting in surgery if you could swallow the surgeon."

Today, that idea isn’t so wild. A research team led by professor Hao Yan from the School of Molecular Sciences and the Biodesign Institute at Arizona State University has moved the field closer toward Feynman's vision; they have developed a DNA nanodevice that can selectively target cancer cells and deliver specific intracellular treatments.

Nanotechnology has developed into a major field of research and medicine. DNA nanotechnology, a subfield that originated 40 years ago, uses designed DNA molecules as a scaffold to build nanostructures and devices through self-assembly.

Yan noted, “An important challenge in intracellular medicine is the specific targeting and efficient delivery of drugs to cytoplasm, instead of getting trapped by intracellular sorting organelles. Our approach provides a working solution to address this challenge.”

In their paper "CytoDirect: A Nucleic Acid Nanodevice for Specific and Efficient Delivery of Functional Payloads to the Cytoplasm," recently published in the Journal of the American Chemical Society, the researchers detail the development of the “CytoDirect" platform, a new DNA nanodevice capable of selectively targeting cancer cells and delivering treatment, with promising applications in intracellular medicine. This novel technology harnesses the precision of DNA nanotechnology to efficiently deliver vital medical treatments, including chemotherapy drugs and siRNAs (small interfering RNA molecules), directly into the cytoplasm of targeted cancer cells.

"One of the key innovations in this work,” explained co-author Nicholas Stephanopoulos from the ASU School of Molecular Sciences, “was using a poly(disulfide)-modified DNA strand to facilitate direct cytoplasmic delivery. Thus, the work was an elegant interplay between synthetic chemistry, DNA nanotechnology, modeling and advanced cell biology to create a functional nanodevice."

By integrating disulfide units and HER2 affibodies into a DNA origami structure, CytoDirect ensures rapid delivery to cancer cells and deep tissue penetration. The research demonstrates CytoDirect's capability to effectively transport therapeutic oligonucleotides and small molecule chemotherapy drugs, achieving notable success in gene knockdown and inducing cell apoptosis.

The development of CytoDirect is the result of collaboration and integration of experimentation and modeling utilizing several ASU facilities, including Biodesign Imaging, Flow Cytometry, Mass Spectrometry and the Life Science Electron Microscopy Laboratory.

Petr Sulc, a School of Molecular Sciences and Biodesign Institute researcher, described the importance of their multidisciplinary approach: "Just as you use computer-aided design software when you are developing new buildings, cars or computer parts, it is also of great help to be able to use computer simulations and tools to design functional nanostructures. However, it turns out that biomolecular systems are extremely difficult to model, due to the richness of the interactions they can take. At our center in Biodesign Institute at ASU, we are working closely between theory and experimental groups to develop new, efficient modeling tools to help design these nanostructures, and also make these models accessible to the wider bionanotechnology community."

Just like the "surgeon that you swallow,” this new nanodevice signifies a major leap in the use of DNA nanostructures for targeted disease treatment, offering new, promising avenues for combating cancer.

More Science and technology

 

Crystal Sonic team

ASU startup Crystal Sonic wins Natcast pitch competition

​Crystal Sonic, an Arizona State University startup, won first place and $25,000 at the 2024 Natcast Startup Pitch Competition at the National Semiconductor Technology Center Symposium, or NSTC…

Scientist observing a beaker.

Celebrating '20 Years of Discovery' at ASU’s Biodesign Institute

Editor’s note:The Biodesign Institute at Arizona State University continues to celebrate its landmark 20th anniversary with this fifth installment in its "20 Years of Discovery" series. Each…

Students test black circular inflatable landing pad at a crater site in Flagstaff

Rocket science: Students land opportunity to create inflatable lunar pad for NASA

Editor's note: The ASU AEGIS team won the Best Systems Engineering award — one of two awards given to the six teams that presented at the Las Vegas forum held Nov. 11–12. Sixteen Arizona State…